1. Adams, M.R., et al. “Medroxyprogesterone acetate antagonizes inhibitory effects of conjugatedequine estrogens on coronary artery atherosclerosis.” Arterioscler Thromb Vasc Biol, January 1997, 17 (1): 217-21.

2. Antoneijevic, Irina, et al. “Modulation of the sleep electroencephalogram by estrogen replacement in postmenopausal women.” American Journal of Obstetrics and Gynecology, February 2000: 277.

3. Aparasu, R.R. “Visits to office-based physicians in the United States for medication-related morbidity.” Journal of the American Pharm Asso, May-June 1999, 39 (3): 332-7.

4. Araneo, B., et al. “DHEAS as an effective vaccine adjuvant in elderly humans.” Annals of the New York Academy of sciences, 1995, 774:232-48.

5. Arlt, W., et al. “Dehydroepiandrosterone replacement in women with adrenal insufficiency.” New England Journal of Medicine, September 30, 1999, 341 (14): 1013-20.

6. Badwe, R. A., et al. “Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer.” Lancet, 1991, 337:1261-4.

7. “Timing of surgery with regard to the menstrual cycle in women with primary breast cancer.” Surgical Clinics of North America, October 1999, 79 (5): 1047-59.

8. Baker, Valerie L. “Alternatives to oral estrogen replacement: Transdermal patches, percutaneous gels, vaginal creams and rings, implants and other methods of delivery.” Obstetrics and Gynecology Clinics of North America, June 1994, 21 (2): 271-97.

9. Bailar, John C., and Gornik, Heather. “Cancer undefeated.” New England Journal of Medicine, May 29, 1997 , 336 (22): 1569-74.

10. Barrett-Connor, E., et al. “The epidemiology of DHEAS and cardiovascular disease.” Annals of the New York Academy of Sciences, 1995, 774:259-70.

11. “Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: the Rancho Bernardo Study.” Journal of the American Geriatric Society, June 1999, 47 (6): 685-91.

12. Bartsch, C., and Bartsch, H. “Melatonin in cancer patients and in tumour-bearing animals.” Advances in Exper Med Biol, 1999, 467: 247-64.

13. Batt, Sharon, and Gross, Liza. “Cancer, Inc.” Sierra Magazine, September/October 1999: 36.

14. Baulieu, E. E., et al. “Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue.” Proceedings of the National Academy of Sciences USA, April 11, 2000, 97 (8) 4279-84.

15. Baum, A. L. “Selective serotonion –reuptake inhibitors in pregnancy and lactation.” Harvard Review of Psychiatry, September 1996, 4 (3): 117-25.

16. Bilimoria, M. M., et al.  “Estrogen replacement therapy and breast cancer: analysis of age of onset and tumour characteristics.” Annals of Surgical Oncology, 1999, 6:200-7

17. Bluming, A. Z., et al. “Hormone replacement therapy in women with previously treated primary breast cancer.” Proceedings of the Annual Meeting of the American Society of Clinical Oncology, 1994, Abstract A137.

18. Bonnier, P., et al. “Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy.” Obstetrics and Gynecology, 1995, 85: 11.

19. Bradlow, H. L., et al. “Indole-3-carbinol: A novel approach to breast cancer prevention.” Appearing in “Cancer Prevention. From the Laboratory to the Clinic: Implications of Genetic, Molecular and Preventive Research,” Annals of the New York Academy of Sciences, September 1995, 768:180-200. And also: “Mulifunctional aspects of the action of indole-3-carbinol as an antitumor agent,” Annals of the New York Academy of Sciences, 1999, 889: 204-13.

20. Brody, Jane E. “Restoring ebbing hormones may slow ageing.” New York Times, July 18, 1995, C1.

21. Brown, N. M., et al. “Prenatal TCDD and predisposition to mammary cancer in the rat.” Carcinogenesis, September 1998, 19 (9): 1623-9.

22. Bush, Trudy L. “Preserving cardiovascular benefits of hormone replacement therapy.” Journal of Reproductive Medicine, March 2000, 45, 3 (Supplement): 259-72.

23. Buster, J. E., et al. “Postmenopausal steroid replacement with micronized dehydroepiandrosterone: preliminary oral bioavailability and does proportionality studies,” American Journal of Obstetrics and Gynecology, 1992, 166: 1163-68.

24. Carlson, L.E., et al. “Relationships between dehydroepiandrosterone sulfate (DHEAS) and cortisol (CRT) plasma levels and everyday memory in Alzheimer’s disease patients compared to healthy controls.” Horm Behav, June 1999, 35 (3): 254-63.

25. Cass, Hyla, and McNally, Terrence. Kava. Rocklin, Cal.: Prima Publishing, 1998.

26. Castelo-Branco, C., et al. “Long-term compliance with estrogen replacement therapy in surgical postmenopausal women.” Menopause, Winter 1999, 6 (4): 307-11.

27. Cavalieri, E. L., et al., “Molecular origin of cancer: catechol estrogen-3, 4-quinones as endogenous tumor initiators.” Proceedings of the National Academy of Sciences, September 30, 1997, 94 (20): 10937-42.

28. Chakmakjian, Z. H., and Zahariah, N. Y. “Bioavailability of progesterone with different modes of administration.” Journal of Reproductive Medicine, June, 1987, 32 (6): 443-47.

29. Chang, K. J., et al. “Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo.” Fertility and Sterility, April 1995, 63 (4): 785-91.

30. Claustrat, B., et al. “Melatonin and jet lag: confirmatory result using a simplified protocol.” Biol Psychiatry, 1992, 32: 705-11.

31. Colditiz, G. A., et al. “Hormone replacement therapy and breast cancer risk.” American Journal of Obstetrics & Gynecology, 1993, 168: 1473-80.

32. Collaborative Group on Hormonal Factors in Breast Cancer. “Breast cancer and hormonal replacement therapy: Collaborative reanalysis of data 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer.” Lancet, 1997, 350: 1047-59.

33. Cooper, A., et al. “Systemic absorption of progesterone from Progest cream in postmenopausal women.” Lancet, April 25, 1998, 351 (9111): 1255-6.

34. Coulan, C. B., et al. “Chronic anovulation may increase postmenopausal breast cancer risk.” Journal of the American Medical Association, 1983, 249: 445-6.

35. Cowan, L. D., et al. “Breast cancer incidence in women with a history of progesterone deficiency.” American Journal of Epidemiology, August 1981, 114 (2): 209-17.

36. Cromer, B. A. “Effects of hormonal contraceptives on bone mineral density.” Drug Safety, March 1999, 20 (3): 213-22.

37. Cundy, T., et al. “Spinal bone density in women using depot medroxyprogesterone contraception.” Obstetrics and Gynecology, October 1998, 92 (4 pt 1): 569-73.

38. Davelaer. “Exogenous estrogen (E2) subcutaneous protective?” Tijdschr Geneeskd, 1991, 135 (14): 613-15.

39. Dew, J., et al. “A cohort study of hormonal replacement therapy given to women previously treated for breast cancer.” Climacteric, 1998, 1: 137-42.

40. DiSaia, P. J., et al. “Hormone replacement in breast cancer.” Lancet, 1993, 342:1232.

41. ”Hormone replacement therapy in breast cancer survivors: A cohort study.” American Journal of Obstetrics and Gynecology, 1996, 174:1494-98.

42. Dollins, A. B., et al. “Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance.” Proceedings of the National Academy of Sciences, 1994, 91: 1824-28.

443. Eden, J. A., et al. “A case-controlled study of combined continuous estrogen-progestin replacement therapy amongst women with a personal history of breast cancer.” Menopause, 1995, 2: 67-72.

44. Ewertz, M. “Influences of noncontraceptive exogenous sex hormones on breast cancer risk in Denmark.” Cited by Gambrell, presentation paper.

45. Feldman, D. L., et al. “Cytoplasmic glucocorticoid binding proteins in bone cells.” Endocrinology, 1975, 96:29-36.

46. Fishman, J., et al. “Increased estrogen-16-alpha-hydroxylase activity in women with breast and endometrial cancer.” Journal of Steroidal Biochemistry, April 1984, 20 (4B): 1077-81.

47. Fitzpatrick, Lorraine, and Good, Andrew. “Micronized progesterone: clinical indications and comparision with current treatments.” Fertility and Sterility, September 1999, 72 (3): 389-97.

48. Folkard, S.,  Arendt, J.,  et al. “Can melatonin improve shift workers’ tolerance of the night shift? Some preliminary findings.” Chronobiology Int.,  1993, 10: 315-20.

49. Foidart, J., et al. “Estradiol and progesterone regulate the proliferation of human breast epithelial cells.” Fertility and Sterility, May 1998, 69 (5): 963-68.

50. Food and Drug Administration. “Tampons and asbestsos, dioxin & toxic shock syndrome.” Report from the Center for devices and Radiological Health, July 23. 1999.

51. Formby, B., and Wiley, T. S. “Progesterone inhibits growth and induces apoptosis in breast cancer cells: inverse effects on Bcl-2 and p53.” Annals of Clinical Laboratory Sci, November-December 1998, 28 (6): 360-9.

52. “Bcl-2, surviving and variant CD44 v7-v10 are downregulated and p53 is upregulated in breast cancer cells by progesterone: inhibition of cell growth and induction of apoptosis.” Mol Cell Biochem, December 1999, 202 (1-2): 53-61.

53. Fortunati, N. “Sex hormone-binding globulin: Not only a transport protein.” Journal of Endocrine investigation, March 1999, 22 (3): 223-34.

54. Franceschi, S., et al. “The role of energy and fat in cancers of the breast and colon-rectum in a southern European population.” Annals of Onocology, 1999, 10 Supplement 6: 61-3.

55. Gaby, Alan R. Preventing and Reversing Osteoprorosis. Rocklin, Cal.: Prima Publications, 1995.

56. Gajdos, Csaba, et al. “Breast cancer diagnosed during hormone replacement therapy.” Obstetrics and Gynecology, April 2000, 95 (4): 513-18.

57. Gambrell, R. Don, et al. “Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users.” Obstetrics-Gynecology, October 1983, 62(4):435-35.

58. Gambrell, R. Don, Jr. “Hormone replacement therapy and breast cancer.” Maturitas, August 1987, 9 (2): 123-33.

59. “Hormone replacement and breast cancer risk.” Archives of Family Medicine, June 1996, 5: 341-50.

60. “Breast cancer and HRT. “Presentation for medical conference, April 2000.

61. Hargrove, Joel T., et al. “Absorption of oral progesterone is influenced by vehicle and particle size.” American Journal of Obstetrics and Gynecology, 1989, 161 (4): 948-51.

62. “Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone.” Obstetrics and Gynecology, April 1989, 73 (4): 606-12.

63. Helzlsouer, Kathy, et al.  “Relantionship of prediagnostic serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer.” Cancer Research, January, 1992, 52:1-4.

64. Holli, K., et al. “Low biologic aggressiveness in breast cancer in women using hormone replacement therapy.” Journal of Clinical Oncology, 1998, 16:3115-20.

65. Holmes, Michelle D., et al. “Association of dietary intake of fat and fatty acids with a risk of breast cancer.” Journal of the American Medical Association, March 10, 1999, 281 (10): 914-20.

66. Hortobagyi, G. I., et al. “Sequential cyclic combined hormonal therapy for metastatic breast cancer.” Cancer, 1989, 64: 1002-6.

67. Hulley, S., et al. “Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post menopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research group.” Journal of the American Medical Association, August 19, 1998, 280, (7): 605-13.

68. Johannes, C. B., et al. “Relation of dehydroepiandrosterone and dehydroepiandrosterone sulfate with cardiovascular disease risk factors in women: longitudinal results from the Massachusetts Women’s Health Study.” Journal of Clinical Epidemiology, February 1999, 52 (2): 95-103.

69. Johnson, Kate. “ERT halves testosterone levels,  may warrant Tx.” Ob-Gyn News, May 15, 2000, 35 (10): 18.

70. Jorgensen, Jens, et al. “Three years of growth hormone treatment in growth hormone-deficient adults: near normalization of body composition and physical performance.” European Journal of Endocrinology, 1994, 130: 224-8.

71. Kall, M. A., et al. “Effects of dietary broccoli on human drug metabolizing activity.” Cancer letters, March 19, 1997, 114 (1-2): 169-70.

72. Khalsa, Dharma Singh, with Stauth, Cameron. Brain Longevity. New York: Warner Books, 1997.

73. Kidd, Parris. “Phosphatidylserine.” New Canaan, Conn.: Keats Publishing, 1998.

74. Klatz, Ronald, and Goldman, Robert. Stopping the Clock. New Canaan, Conn.: Keats Publishing, 1996.

75. Lane, G., et al. “Dose-Dependant effects of oral progesterone on the oestrogenised post menopausal endometrium.” British Medical Journal, 1983, 287: 1241-44.

76. Lavigne. J. A., et al. “An association between the allele coding for a low activity variant of catechol-O-methyl transferase and the risk for breast cancer.” Cancer Research, December 15, 1997, 57 (24): 5493-7.

77. Lee, John R., and Hopkins, Virginia. What Your Doctor May Not Tell You About Menopause: The Breakthrough Book on Natural Progesterone. New York: Warner Books, 1996.

78. Lee, John R. “Women’s heart disease, heart attacks and hormones.” The John R. Lee, MD Medical Letter, August 1998: 1-3.

“Sleep surviving and breast cancer.” The John R. Lee, MD Medical Letter, April 2000: 6.

Legros, S., et al. “Premenstrual tension syndrome or premenstrual dysphoria.” Review Med Liege, April 1999, 54 (4): 268-73.

Leis, H. P., Jr. “Endocrine prophylaxis of breast cancer with cyclic estrogen and progesterone.” International Surgery, may 1966, 45 (5): 496-503.

Lemon, H. M. “Clinical and experimental aspects of the anti-mammary carinogenic activity of estriol.” Frontier Horm Research, 1977 (5):155-73.

“Pathophysiologic consideration in the treatment of menopausal patients with estrogens: the role of estriol in the prevention of mammary carcinoma.” Acta Endocrinol Suppl (Copenhagen), 1980,  233:17-27.

“Antimammary carcinogenic activity of 17-alpha-ethinyl estriol.” Cancer, 1987, 60: 2873-81.

Lemon, H. M., et al. “Inhibition of radiogenic mammary carcinoma in rats by estriol or tamoxifen.” Cancer, 1989, 63: 1685-92.

Lissoni, P., et al. “Randomized study with the pineal hormone melatonin versus supportive care alone in advianced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin.” Oncology, 1992, 49: 336-39.

“Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumor patients with poor clinical status.” European Journal of Cancer, November 1999, 35 (12): 1688-92.

Lauritzen, C. “Ostrogensubsitution in der postmenopause vor und nach behandeltem genital-und mammakazinom.” Menopause Hormonsubsitution Heute, 1993, 6:76-88.

Magnusson, C., et al. “Prognostic characteristics in breast cancers after hormone replacement therapy.” Breast Cancer Research and Treatment, 1996, 38: 325-34.

Marsden, J., et al “Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible?” Fertility and Sterility, 2000, 73: 292-99.

Mauvais-Jarvis, P., et al. “Luteal phase defect and breast cancer genesis.” Breast Cancer Research and Treatment, 1982, 2: 139.

Michnovicz, J. J., and Bradlow, H. L. “Induction of estradiol metabolism by dietary indole-3-carbinole in humans.” Journal of The National Cancer Institute, June 6, 1990, 82 (11): 947-49.

Miyagawa, K., et al. “Medroxyprogesterone acetate interferes with ovarian steroid protection against coronary vasospasm.” Nature Medicine, 1997, 3: 324-27.

Mohr, P. E., et al. “Serum progesterone and prognosis in operable breast cancer.” British Journal of Cancer, June 1996, 73 (12): 1552-55.

Monteleone, P., et al. “Allopregnanolone concentrations and premenstrual syndrome.” European Journal of Endocrinology, March 2000, 142 (3): 269-73.

Moon, Mary Ann. “HRT users more prone to mammography failure.” Ob-Gyn News, May 15, 2000, 35 (10): 1.

__. “Breast density predicts mammography failure.” Ob-Gyn News, May 15, 2000, 35 (10): 1.

Morales, A. J., et al. “Effects of replacement dose od dehydroepiandrosterone in men and women of advancing age.” Journal of Clinical Endocrinology and Metabolism, 1994, 78 (6): 1360-67.

Mortola, J. F., et al. “The Effects of dehydroepiandrosterone on endocrine-metabolic parameters in post menopausal women. “Journal of Clinical Endocrinology and Metabolism, 1990, 71: 696-704.

Nachtigall, Lila E. “Emerging delivery systems for estrogen replacement: Aspects of transdermal and oral delivery.” American Journal of Obstetrics and Gynecology, 1995, 173 (3): 993-97.

Nachtigall, M. J., et al. “Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy.” Obstetrics and Gynecology, 1992, 80: 827-30.

Nafziger, Anne, et al. “Longitudinal changes in dehydroepiandrosterone concentrations in men and women.” Journal of Laboratory Clinical Medicine, 1998, 131 (4): 316-23.

Natrajan, P.K., Soumakis, K., and Gambrell, R. D. “Estrogen replacement therapy in women with previous breast cancer.” American Journal of Obstetrics and Gynecology, August, 1999, 181 (2): 288-95.

O’Connor, I. F., et al. “Breast carcinoma developing in patients on hormone replacement therapy: a histological and immunohistological study.” Journal of Clinical Pathol, 1998, 51; 935-38.

Padwick, M. L., et al. “Absorption and metabolism of oral progesterone when administered twice daily.” Fertility and Sterility, 1986, 46: 402-07.

Persson, I., et al. “Combined oestrogen-progestogen replacement and breast cancer risk.” Lancet, 1992, 340: 1044.

__. “Risks of breast and endometrial cancer after estrogen and progestin replacement .” Cancer Causes Control, 1999, 10: 253-60.

Petrie, K., et al. “A double-blind trial of melatonin as a treatment for jet lag in an international cabin crew.” Biol Psychiatry, 1993, 33: 526-30.

Pierpaoli, Walter. “Melatonin, the pineal gland and aging: A planetary and biological reality.” In the Science of Anti-Ageing Medicine (edited by Klatz and Goldman), Colardo Springs, American Academy of Anti-Ageing Medicine, 1996.

Pierpaoli, Walter, and Regelson, William. “The pineal control of aging. The effect of melatonin and pineal grafting on aging mice.” Proceedings of the National Academy of Sciences, 1994, 91: 787-91.

__. The Melatonin Miracle. New York: Pocket Books, 1995.

Plouffe, L., Jr. Ovaries, androgens and the menopause: practical applications.” Seminars of reproductive Endocrinology, 1998, 16 (2): 117-20.

Plu-Bureau, G., et al. “Progesterone use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease.” British Journal of Cancer, 1994, 70: 270-77.

“Percutaneous progesterone use and risk of breast cancer: results from a French cohort study of permenopausal women with benign breast disease.” Cancer Detection and Pervention, 1999, 23 (4): 290-6.

Powles, T.J., et al. “Hormone replacement therapy after breast cancer.” Lancet, 1993, 342: 60-61.

Powrie, Jake, et al. “Growth hormone replacement therapy for growth hormone-deficient adults,” Drugs, 1995, 49 (5): 656-63.

Prior, J. C. “Progesterone as a bine-trophic hormone.” Endocrine Reviews, May 1990, 11 (2): 386-98.

Raz, Raul, and Stamm, Walter. “A controlled trial of intravaginal esteriol in postmenopausal women with recurrent urinary tract infections.” The New England Journal of Medicine,  September 9,  1993,  329 (11): 753-56.

Regelson, William, and colman, Carol. The Superhormone Promise: Nature’s Antidote to Ageing. New York: Pocket Books, 1997.

Roan, Shari. “Hormone found to raise risk of breast cancer.” Los Angeles Times, February 7, 2000.

Ron, E., et al. “Cancer incidence in a cohort of infertile women.” American Journal of Epidemiology, 1987, 125: 780-90.

Rosano, G. M., et al. “Medroxyprogesterone but not natural progesterone reverses the benefical effect of estradiol-17b upon exercise induced myocardial ischemia: a double-blind cross-over study.” Circulation, 1996;94: 1-18.

“Cardiovascular pharmacology of hormone replacement therapy.” Drugs and Ageing, September 1999, 15 (3): 219-34.

Rosen, Thord, et al. “Cardiovasular risk factors in adult patients with growth hormone deficiency.” Acta Endocrinologica, 1993, 129: 195-200.

Rosen, Thord, et al. “Consequences of growth hormone deficiency in adults and the benefits and risks of recombinant human growth hormone treatment,” Hormone research, 1995, 43: 93-99.

Ross, R. K. et al. “Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.” Journal of the National Cancer Insititute, February 16, 2000, 92 (4): 328-32.

Rupprecht, R., et al. “Neuropsychopharmacological properties of neuroactive steroids.” Steroids, January-February 1999, 64 (1): 83-91.

Rylance, P. B., et al. “Natural progesterone and antihypertensive action.” British Medical Journal, January 5, 1985, 290: 13-14.

Salmon, R. J., et al. Clinical and biological characteristics of breast cancers in postmenopausal women receiving hormone replacement therapy.” Oncology Rep, 1999, 6: 699-703.

Sarrel, P. M. “Cardiovascular aspects of androgens in women.” Seminars of Reproductive Endocrinology, 1998, 16 (2): 121-8.

“Psychosexual effects of menopause: role of androgens.” American Journal of Obstetrics and Gynecology, March 1999, 180 (3 pt 2): 319-24.

Sarrel, P. M., et al “Vasodilator effects of estrogen are not diminished by androgen in postmenopausal women.” Fertility and Sterility, December 1997, 68 (6): 1123-7.

Schairer, C., Lubin, Jay, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.” Journal of the American Medical Association, January 26, 2000, 283 (4): 485-91.

Seelig, Mildred. “Interrelationship of magnesium and estrogen in cardiovascular and bone disorders, eclampsia, and premenstrual syndrome.” Journal of the American College of Nutrition. 1993, 12 (4): 442-58.

Senie, R. T., et al. “Timing of breast cancer excision during the menstrual cycle and influences duration of disease-free survival. “ Annals of Internal Medicine, 1991, 115: 337-42.

“The timing of breast cancer surgery during the menstrual cycle.” Oncology, October 1997, 11 (10): 1509-17.

Service, Robert F. “New role for estrogen in cancer?” Science, March 13, 1998, 279: 1631-33.

Shaywitz, Sally, et al. “Effects of estrogen on brain activation patterns in postmenopausal women during working memory tasks.” Journal of the American Medical Association, 1999, 281: 1197-1202.

Sherwin, B. B. “The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women.” Journal of Clinical Endocrinology and Metabolism, February 1991, 72 (2): 336 -43.

“Sex hormones and psychological functioning in postmenopausal women.” Exp Gerontol, 1994, 29 (3-4): 423-30.

“Can estrogen keep you smart? Evidence from clinical studies.” Journal of Psychiatry Neuroscience, September 1999, 24 (4): 315-21.

Shimada, T., et al. “Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1.” Cancer Research, July 1996, 56 (13): 2979-84.

Siegal, Sanford. Is Your Thyroid Making You Fat? New York: Warner books, 2000.

Smith, Sheryl, et al. “GABA receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid.” Nature, 1998, 392: 926-30.

Speroff,  Leon. “Postmenopausal estrogen-progestin therapy and breast cancer: a clinical response to an epidemiological report.” Contempary Ob/Gyn, March 2000: 103-121.

Stanford, J. L. Weiss, N. S., et al. “Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women.” Journal of the American Medical Association, 2000, 283:485-91.

Steenland, Kyle, et al. “Cancer, heart disease, and diabetes in workers exposed to 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin.” Journal of the National Cancer Institute, May 5, 1999, 91 (9): 779-86.

Taylor, Maida. “Alternatives to conventional hormone replacement therapy.” Comprehensive Therapy, 1997, 23 (8): 514-32.

Vaccarino, V., et al. “Sex-based differences in early mortality after myocardial infarction.” New England Journal of Medicine, July 22, 1999, 341 (4): 217-25.

Van Vollenhoven, R. F., et al. “An open study of dehydroepiandrostrone in systemic lupus erythematosus.” Arthritis Rheum, 1994, 37: 1305-10.

Wagner, Janice. “Rationale for hormone replacement therapy in atherosclerosis prevention.” The Journal of reproductive Medicine, March 2000. 45 (3 Supplement): 245-58.

“Cardiovascular considerations for hormone replacement therapy.” International Journal of Fertility, March 2000, 45 (Supplement 1); 73-80.

Wallis, Claudia. “The estrogen dilemma.” Time, June 26, 1995. Cover article.

Watts, N. B., et al. “Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause.” Obstetrics and Gynecology, April 1995, 85 (4): 529-37.

Welty, F. K. “Who should receive hormone replacement therapy? Journal of Thrombolysis, 1996, 3 (1): 13-21.

Wexler, Laura. “Studies of acute coronary syndromes in women-Lessons for everyone.” New England Journal of Medicine, July22, 1999, 341 (4): 275-6.

Wile, A. G., et al. “Hormone replacement therapy in previously treated breast cancer patients.” American Journal of Surgery, 1993, 165: 372-75.

Williams, Timothy, and Frohman, Lawrence. “Potential therapeutic indications for growth hormone-releasing hormone in conditions other than growth retardation.” Pharmacotherapy, November/December 1986, 6 (6): 311-16.

Willett, Walter. “Dietary fat and breast cancer.” Toxicol Sciences, December 1999, 52 (2 supplement): 127-46.

Willett, Walter, et al. “Postmenopausal estrogens-opposed, or none of the above.” Journal of the American Medical Association, January 26, 2000, 283, (4): 534-5.

Willis, Dawn, et al. “Estrogen replacement therapy and risk od fatal breast cancer in prospective cohort of postmenopausal women in the United States.” Cancer Causes Control, July 1996, 8 (4): 672.

Wright, Jonathan V., and Morgenthaler, John. Natural Hormone Replacement. Petaluma, Cal.: Smart Publications, 1997.

Yen, S. S., et al. “Replacement of DHEA in aging men and women. Potential remedial effects.” Annals of the New York Academy of Sciences, 1995, 774: 128-42.

Zinder, O., et al. “Neuroactive steroids: their mechanism of action and their function in the press response.” Acta Physiol Scand, November 1999, 167 (3): 181-8.